A5023804982- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Advanced biosensing and bioanalysis techniques
- Insect symbiosis and bacterial influences
- COVID-19 Clinical Research Studies
- Insect Resistance and Genetics
- Horticultural and Viticultural Research
- Vaccine Coverage and Hesitancy
- CRISPR and Genetic Engineering
- Biosensors and Analytical Detection
- ATP Synthase and ATPases Research
- Gold and Silver Nanoparticles Synthesis and Applications
- Plant tissue culture and regeneration
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- Mesoporous Materials and Catalysis
- Catalytic Processes in Materials Science
- HIV/AIDS Research and Interventions
- Polysaccharides Composition and Applications
- Plant biochemistry and biosynthesis
- Respiratory viral infections research
- Photosynthetic Processes and Mechanisms
- Proteins in Food Systems
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
Chinese Academy of Sciences
2016-2025
Pfizer (United States)
2020-2025
Institute of Genetics and Developmental Biology
2017-2025
Huaihua University
2025
Ithaca College
2021-2025
Cornell University
2021-2025
ZheJiang Academy of Agricultural Sciences
2021-2025
Zhejiang Sci-Tech University
2025
Beijing National Laboratory for Molecular Sciences
2019-2024
University of Chinese Academy of Sciences
2010-2023
BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. highly efficacious against disease 2019 (Covid-19) and currently approved, conditionally or authorized for emergency use worldwide. At the time of initial authorization, data beyond months after vaccination were unavailable.In an ongoing, placebo-controlled, observer-blinded,...
BackgroundUntil very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective are needed to protect this population, facilitate in-person learning and socialization, contribute herd immunity.MethodsIn ongoing multinational, placebo-controlled, observer-blinded trial, we randomly assigned participants a 1:1 ratio receive two injections, 21 days apart, 30 μg...
Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.A phase 1, dose-finding study and an ongoing 2-3 randomized trial being conducted to investigate the safety, immunogenicity, efficacy two doses BNT162b2 vaccine administered 21 days apart 6 months 11 age. We present results for 5-to-11-year-old children. In trial, participants were randomly assigned a 2:1 ratio receive either at dose level identified during...
Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during disease 2019 (Covid-19) pandemic. In light of reports waning protection occurring 6 months after primary two-dose series, data are needed on safety and efficacy offering third (booster) dose in persons 16 years age or older.
ABSTRACT Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. highly efficacious against COVID-19 and currently authorized for emergency use or conditional approval worldwide. At the time of authorization, data beyond 2 months post-vaccination were unavailable. Methods In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, 44,165...
Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated.
The emergence of immune-escape variants severe acute respiratory syndrome coronavirus 2 warrants the use sequence-adapted vaccines to provide protection against disease 2019.
Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. We conducted a phase 1 dose-finding study conducting an ongoing 2-3 safety, immunogenicity, efficacy trial of the BNT162b2 vaccine healthy children 6 months to 11 years age. present results for less than 2 age those 4 through data-cutoff dates (April 29, 2022, safety immunogenicity June 17, efficacy). In trial, participants were randomly assigned (in 2:1 ratio) receive two 3-μg...
Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of ongoing, open-label, phase 2/3 study monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg dose). Healthy participants ≥12 years old (N = 412 (12–17 years, N 30; 18–55 174; >55 208)) who previously received ≥3 doses US-authorized mRNA vaccine, the most recent being BA.4/BA.5-adapted bivalent vaccine ≥150 days before vaccination, were...
This paper reports the fabrication and characterization of polymer nanofibers embedded with gold nanorods in uniaxial alignment for applications optical waveguiding sensing. Using a approach, we demonstrated highly efficient excitation localized surface plasmon resonance photon-to-plasmon-conversion efficiency as high 70% single nanorod at its longitudinal wavelength. On basis nanorods, further compact humidity sensors response time 110 ms an operation power low 500 pW.
We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part a combination regimen in the ongoing STARTMRK study treatment-naive patients infected human immunodeficiency virus (HIV).Eligible HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, emtricitabine were randomized double-blind, noninferiority receive each combined tenofovir/emtricitabine. Outcomes included viral suppression, adverse events, changes from metabolic...
Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, has favorable unique in vitro resistance profile. DRIVE-AHEAD phase 3, double-blind, non-inferiority trial. Antiretroviral treatment–naive adults with ≥1000 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine 300 tenofovir disoproxil fumarate (TDF) mg...
Terahertz (THz) waves, especially those assisted by THz metamaterials, have great potential for detecting trace amounts of sensing targets. Some nanomaterials, such as gold nanoparticles (AuNPs), also show promising characteristics; however, their application in this context is hindered a lack plasmonic activity the region. This study first to introduce AuNPs into metamaterial applications new tool improving sensitivity protein detection. We demonstrate mechanism detection through different...
Multiple-enzyme-involving cascade reactions that yield bioenergy are necessary in natural oxidative phosphorylation. However, vitro applications hampered by the sensitivity of catalytic activity to environmental adaptation. Herein, we explore nanozyme-catalyzed an assembled hybrid architecture for mitochondria-mimicking Hollow silica microspheres containing trapped gold nanoparticles were synthesized promote two enzyme-like transform glucose into gluconic acid presence oxygen. The resulting...
The Russian dandelion Taraxacum kok-saghyz Rodin (TKS), a member of the Composite family and potential alternative source natural rubber (NR) inulin, is an ideal model system for studying biosynthesis. Here we present draft genome TKS, first assembled NR-producing weed plant. TKS assembly has length 1.29 Gb, containing 46 731 predicted protein-coding genes 68.56% repeats, in which LTR-RT elements predominantly contribute to enlargement. We analyzed heterozygous regions/genes, suggesting its...